FindTrial
Sign In

Effect of Anti-HLA-C autoantibodies on primary platelet transfusion refractoriness in patients with hematologic disorders

Effect of Anti-HLA-C autoantibodies on primary platelet transfusion refractoriness in patients with hematologic disorders

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077945
Enrollment
Unknown
Registered
2023-11-24
Start date
2023-12-01
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myelodysplastic syndrome

Interventions

The platelet transfusion refractoriness:N/A
The effective platelet infusion:N/A

Sponsors

Zhejiang Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patient meets the diagnostic criteria for hematological diseases. 2. Agreed to platelet infusion therapy, completed all tests, and received HLA high-resolution genetic testing and antibody testing. 3. Having two or more platelet transfusions for treatment 4. There was no clear history of blood transfusion before admission.

Exclusion criteria

Exclusion criteria: 1) Incomplete general information and blood transfusion information 2) Patients with incomplete pre and post transfusion evaluation indicators.

Design outcomes

Primary

MeasureTime frame
Platelet concentration;—

Countries

China

Contacts

Public ContactWu Dijiong

Zhejiang Provincial Hospital of Traditional Chinese Medicine

wdj850@163.com+86 571 8707 3569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026